– USA, NC – Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that James Mitchum has been nominated to be elected to the Company’s Board of Directors at the annual meeting of stockholders scheduled for September 15, 2015.
Mr. Mitchum is an experienced, highly-regarded pharmaceutical executive and has served as the chief executive officer of Heart to Heart International, a non-profit humanitarian organization, since September 2014. From 2009 to July 2012, Mr. Mitchum served as president of the Americas for EUSA Pharma (USA), Inc., where he oversaw the streamlining of that business as well as the development, FDA approval and successful launch of a pediatric oncology drug in 2011. Previously, he served as president and chief executive officer of Enturia, Inc., a privately owned drug-device company based in Kansas City. From 2003 to 2005, Mr. Mitchum served as the president and chief executive officer of Sanofi-Aventis Group Japan, and he was chief executive for Aventis Pharma UK from 2000 through 2002. He has also worked in a variety of other senior financial roles. Mr. Mitchum currently serves as a director for NephroGenex Inc., a company developing drugs to treat kidney disease, and has also served as a director on numerous private company and organization boards. He holds an M.B.A. from the University of Tennessee and a B.S. in Business and Math from Milligan College.
“We believe that the election of James Mitchum to our Board of Directors will be a significant and very positive addition for the Company,” said John Kelley, chief executive officer of Tenax. “His experience leading companies in the life sciences industry, as well as his financial and operational expertise, will be a great resource for us as we continue to execute on our late-stage development programs for levosimendan.”
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The Company is currently enrolling a Phase 3 trial with levosimendan in that indication, and is also supporting Imperial College London’s ongoing LeoPARDS trial for levosimendan in septic shock.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
